INSM Insmed, Inc.
XNAS
114.75
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
INSM
$114.75
—
What changed
Recent filings, trades and movesKey stats
$114.75
- 52-Week Range
- $90.39 – $212.75
- YTD
- -35.21%
- IV Rank (30D)
- 35.38
- Straddle Price
- $14.00
- P/C Vol Ratio
- 0.18
- Market Cap
- $25.1B
- Open
- $114.83
- Day Range
- $112.61 – $116.36
- Volume
- 1,442,132
- Prev Close
- $114.41
Fair Value
MODEL: SHORT
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.84 |
| Cost of Equity (CAPM) | 9.10% (VRP-adj) |
| WACC | 9.11% |
| Volatility Risk Premium | -0.5pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.6B |
| Return on Equity (TTM) | -83.4% |
| Book / Price | 2.9% |
| Gross Margin (TTM) | 84.4% |
| FCF Margin (TTM) | -41.3% |
| Debt / Equity | 0.77 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $111.21 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $100.92 |
| Bollinger Width / SMA20 | 28.3% (drives anchor stability) |
| Net Debt | $0.2B |
| Market Cap | $25B |
Peers used for multiples: AMGN, GH, GILD, LLY, MRNA, NTRA, TEVA, VRTX
60-Day Conviction
32%
20-Day Fair Value
≈ by Dec 8, 2026
$114.24
α -0.6%
rank 26%
conviction
45%
40-Day Fair Value
≈ by Jan 6, 2027
$114.08
α -0.8%
rank 26%
conviction
29%
60-Day Fair Value
≈ by Feb 4, 2027
$113.61
α -1.2%
rank 26%
conviction
32%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.3× · 4 peers |
| Peer EV/EBITDA | n/a | 0% | median 27.1× · 5 peers |
| Peer P/B | $52.91 | 21% | median 15.9× · 7 peers |
| Peer P/S | $94.29 | 21% | median 12.3× · 8 peers |
| Market Anchor (SMA50) | $111.21 | 9% | stability 8% (BB-width) |
| Options Expected (B-L 30d) | $114.77 | 50% | 19 strikes · skew +0.25 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $25.1B
- Employees
- 1,664
- List Date
- 2000-06-01
- CIK
- 0001104506
- Last Earnings
- Oct 29 before open · +15.1% vs ±17.1% expected
- Next Earnings
- ~Feb 18, 2027 (estimated)
- Headquarters
- Bridgewater, NJ
- Homepage
- https://www.insmed.com
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, prote…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 12.48% | -19.37% | 12.25% | -7.15% | 9.48% | -11.43% | -0.62% |
| Feb | -4.46% | 0.80% | -5.74% | -2.84% | 4.71% | -3.02% | -1.76% |
| Mar | -9.73% | -2.04% | -15.76% | -3.31% | 0.00% | 11.76% | -3.18% |
| Apr | -4.83% | -10.22% | 12.26% | -7.49% | 0.00% | -17.31% | -4.60% |
| May | -25.32% | -16.17% | -5.65% | 115.12% | -4.01% | -19.77% | 7.37% |
| Jun | 13.07% | 9.98% | 9.67% | 19.77% | 40.40% | 0.56% | 15.58% |
| Jul | -16.53% | 5.89% | 6.46% | 9.66% | 9.90% | -8.10% | 1.21% |
| Aug | 16.20% | 17.91% | -1.08% | 1.51% | 25.22% | 23.74% | 13.92% |
| Sep | -5.46% | -14.49% | 11.53% | -0.42% | -0.89% | -6.07% | -2.63% |
| Oct | 10.12% | -21.84% | -1.22% | -7.68% | 28.73% | 3.67% | 1.96% |
| Nov | -11.37% | 5.66% | 0.12% | 10.01% | 11.57% | 5.09%* | 3.51% |
| Dec | 2.06% | 4.50% | 16.86% | -4.67% | -17.68% | -- | 0.21% |
| Total | -28.80% | -39.28% | 40.54% | 123.13% | 149.14% | -25.47% | 36.54% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $101.74
SMA 50: $111.14
SMA 200: $123.94
Current: $115.00
EMA 12: $107.49
EMA 26: $106.28
MACD: 1.2142 | Signal: 2.4853
BEARISH
ADX (14): 31.75
TREND
+DI: 29.91
−DI: 20.65
Momentum Oscillators
RSI (14): 61.45
NEUTRAL
Stoch %K: 84.64
Stoch %D: 75.30
Williams %R: -5.75
Volume & Volatility
BB Upper: $117.24
BB Lower: $86.25
NEUTRAL
OBV: 58,222,944
Vol SMA 20: 3,803,427
Vol ROC: -57.91%
ATR: $5.03
True Range: $3.75
HV 20: 63.2%
HV 30: 59.9%
HV 60: 49.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before INSM’s Oct 29 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers: Recent news sentiment has been mixed, with positive developments in the interstitial lung disease market countered by negative headlines related to the Nasdaq-100 Index. The technical picture is neutral, with a strong trend regime but no clear breakout or breakdown signals.
Primary Risks: Earnings miss or negative guidance, regulatory issues affecting the pharmaceutical industry, and potential volatility spikes driven by changes in interest rates or macroeconomic trends.
Investment Thesis: INSM has potential for long-term growth due to its presence in the interstitial lung disease market. However, short-term volatility and mixed news sentiment create uncertainty around the stock's immediate direction.
Recent News Sentiment Impact: The recent negative headlines have weighed on the stock price, but the positive developments in the interstitial lung disease market could lead to a bounce if earnings are met or exceeded.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Neutral
- Medium-term (1-3 months): Uptrend
- Long-term (3-12 months): Bullish
Support/Resistance Levels: The stock is currently trading near its lower Bollinger Band, with potential support at $92.46. Resistance lies at the upper band ($114.57).
Momentum Signals:
- RSI interpretation: Neutral (38.39)
- MACD signal: Bearish (-7.61 / Signal: 0.37 / Histogram: -7.97)
- Bollinger Bands position: Mean reversion
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been mixed, with negative sentiment dominating the past few weeks.
Sentiment Assessment: Neutral (2/3 positive, 1/3 negative)
Catalyst Identification: Earnings, product launches, and regulatory changes could drive future movements.
Market Narrative: The market is currently pricing in a $13.60 move by expiration, indicating potential volatility ahead.
Risk & Volatility Assessment
Beta Interpretation: INSM has a relatively low beta of 0.66 compared to the SPY (S&P 500), indicating lower risk and greater stability.
Volatility Regime: The stock is currently experiencing moderate volatility, with an IV rank of 43.8% and a historical volatility of 78.9%.
Options Market Signals:
- IV Premium vs HV30: -20.0% (positive = implied richer than realized)
- Put/Call Volume Ratio: 1.29 (Neutral sentiment)
Market Context & Positioning
Sector Performance: INSM is performing relatively well within the pharmaceutical sector.
Institutional Activity: Institutional interest is moderate, with a volume flow of 384 calls vs 495 puts and open interest of 3,409 calls vs 3,413 puts.
Correlation Analysis: The stock has a low correlation coefficient of 0.16 compared to the SPY (S&P 500), indicating greater independence from market trends.
Relative Valuation: INSM is positioned within its trading range, with potential support at $92.46 and resistance at $114.57.
Key Levels & Action Items
Critical Price Levels:
- Support: $92.46
- Resistance: $114.57
Breakout/Breakdown Levels: A breakout above the upper Bollinger Band could signal a bullish trend, while a breakdown below the lower band could indicate a bearish trend.
Time-Sensitive Catalysts: Earnings and product launches could drive future movements.
Risk Management: Stop-loss levels should be set at $85.00 (1 standard deviation below current price), and position sizing considerations should prioritize risk management.
Please note that this analysis is based on the provided data, but it does not constitute buy/sell advice.
Generated
News
All INSM news →
BRINSUPRI revenue surged to $400.1 million, driving 268% total revenue growth year-over-year.
Earnings History
16 of 20 under expected move
Avg Expected Move
11.46%
Avg Actual Move
7.37%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-25 | Pre-Market | 14.86% | 7.17% | 0.48x | Within |
| 2021-05-06 | Pre-Market | 19.63% | 6.49% | 0.33x | Within |
| 2021-08-05 | Pre-Market | 5.49% | 2.18% | 0.40x | Within |
| 2021-10-28 | Pre-Market | 9.28% | 12.08% | 1.30x | Exceeded |
| 2022-02-17 | Pre-Market | 8.54% | 2.00% | 0.23x | Within |
| 2023-02-23 | Pre-Market | 11.58% | 2.49% | 0.22x | Within |
| 2023-05-04 | Pre-Market | 9.95% | 1.21% | 0.12x | Within |
| 2023-08-03 | Pre-Market | 10.11% | 1.75% | 0.17x | Within |
| 2023-10-26 | Pre-Market | 10.73% | 0.39% | 0.04x | Within |
| 2024-02-22 | Pre-Market | 11.26% | 3.86% | 0.34x | Within |
| 2024-05-09 | Pre-Market | 16.54% | 1.46% | 0.09x | Within |
| 2024-08-08 | Pre-Market | 8.38% | 1.16% | 0.14x | Within |
| 2024-10-31 | Pre-Market | 9.32% | 4.29% | 0.46x | Within |
| 2025-05-08 | Pre-Market | 9.78% | 3.88% | 0.40x | Within |
| 2025-08-07 | Pre-Market | 10.70% | 1.76% | 0.16x | Within |
| 2025-10-30 | Pre-Market | 10.99% | 16.33% | 1.49x | Exceeded |
| 2026-02-19 | Pre-Market | 7.71% | 6.54% | 0.85x | Within |
| 2026-05-07 | Pre-Market | 12.40% | 23.41% | 1.89x | Exceeded |
| 2026-08-06 | Pre-Market | 14.85% | 33.86% | 2.28x | Exceeded |
| 2026-10-29 | Pre-Market | 17.12% | 15.06% | 0.88x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
INSM Options Activity & IV Rank
INSM IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 48.1%
7-DTE IV: 56.1%
Expected Move: $14.00
7-DTE Move: $8.95
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 8,191
Put Volume: 1,452
P/C Volume: 0.177
BULLISH
Call OI: 95,241
Put OI: 41,173
P/C OI: 0.432
Total OI: 136,414
ATM Options Pricing
ATM Call: $7.20
ATM Put: $6.80
Call %: 6.3%
Put %: 5.9%
Chain Summary
Chain Volume: 9,643
Chain OI: 136,414
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 91st percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
91%
vs own history
GEX tilt
+0.82
OI-weighted, today
Vanna tilt
+0.29
δ-sensitivity to IV
Charm tilt
-0.34
δ-decay vs time
Charm tilt -0.34: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 47 ATM contracts, 68k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)33.2MediumNov 9
IV Rank (30 DTE)35.4MediumNov 9
Straddle Price (30 DTE)$14.00Nov 9
Beta Analysis
Risk Metrics
Beta: 0.5479
Alpha: -37.88%
Correlation: 0.1196
R-Squared: 1.4%
Stock Volatility: 63.0%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own INSM
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $272.6M | #117 of 6285 | +17.2% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $218.4M | #123 of 3716 | +76.9% | 13F | |
| Duquesne Family Office Family office Stanley Druckenmiller | $151.9M | #4 of 86 | +23.4% | 13F | |
| Point72 Hedge fund Steve Cohen | $57.3M | #291 of 1945 | new | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $48.6M | #82 of 997 | +54.1% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $764K | #1862 of 4729 | -3.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
INSM Institutional Ownership (13F)
Filings for 2026-06-30 · 307 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 216,435,750 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
32 filers$619.53M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Duquesne Family Office LLC | $143.94M | 23.23% | 2026-06-30 |
| 2 | Millennium Management LLC Custodian | $92.12M | 14.87% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $76.30M | 12.32% | 2026-06-30 |
| 4 | Caption Management, LLC | $67.17M | 10.84% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $48.16M | 7.77% | 2026-06-30 |
| 6 | JPMorgan Chase & Co Custodian | $47.66M | 7.69% | 2026-06-30 |
| 7 | Citadel Advisors LLC Custodian | $38.08M | 6.15% | 2026-06-30 |
| 8 | TUDOR INVESTMENT CORP ET AL | $33.08M | 5.34% | 2026-06-30 |
| 9 | IMC-Chicago, LLC Custodian | $15.96M | 2.58% | 2026-09-30 |
| 10 | Eversept Partners, LP | $10.30M | 1.66% | 2026-06-30 |
| 11 | Goldman Sachs Group Inc Custodian | $8.93M | 1.44% | 2026-06-30 |
| 12 | GROUP ONE TRADING LLC Custodian | $6.39M | 1.03% | 2026-06-30 |
| 13 | Stonepine Capital Management, LLC | $5.60M | 0.90% | 2026-06-30 |
| 14 | Simplex Trading, LLC Custodian | $4.17M | 0.67% | 2026-09-30 |
| 15 | PEAK6 LLC | $3.73M | 0.60% | 2026-06-30 |
| 16 | Squarepoint Ops LLC | $3.61M | 0.58% | 2026-06-30 |
| 17 | CAPITAL FUND MANAGEMENT S.A. | $2.31M | 0.37% | 2026-06-30 |
| 18 | Balyasny Asset Management L.P. | $1.78M | 0.29% | 2026-06-30 |
| 19 | D. E. Shaw & Co., Inc. Custodian | $1.60M | 0.26% | 2026-06-30 |
| 20 | MYDA Advisors LLC | $1.60M | 0.26% | 2026-06-30 |
| 21 | Tidal Investments LLC | $1.25M | 0.20% | 2026-06-30 |
| 22 | NOMURA HOLDINGS INC | $1.16M | 0.19% | 2026-06-30 |
| 23 | BNP Paribas Financial Markets Custodian | $1.07M | 0.17% | 2026-06-30 |
| 24 | Walleye Capital LLC | $948.92K | 0.15% | 2026-06-30 |
| 25 | Walleye Trading LLC | $693.03K | 0.11% | 2026-06-30 |
26 filers$410.76M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Goldman Sachs Group Inc Custodian | $81.87M | 19.93% | 2026-06-30 |
| 2 | Caption Management, LLC | $78.97M | 19.23% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $76.67M | 18.67% | 2026-06-30 |
| 4 | JPMorgan Chase & Co Custodian | $45.04M | 10.96% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $36.98M | 9.00% | 2026-06-30 |
| 6 | Citadel Advisors LLC Custodian | $29.18M | 7.10% | 2026-06-30 |
| 7 | IMC-Chicago, LLC Custodian | $14.54M | 3.54% | 2026-09-30 |
| 8 | Jefferies Financial Group Inc. | $12.03M | 2.93% | 2026-09-30 |
| 9 | Parallax Volatility Advisers, L.P. | $10.91M | 2.66% | 2026-06-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $4.98M | 1.21% | 2026-06-30 |
| 11 | D. E. Shaw & Co., Inc. Custodian | $4.81M | 1.17% | 2026-06-30 |
| 12 | 683 Capital Management, LLC | $3.73M | 0.91% | 2026-06-30 |
| 13 | CANTOR FITZGERALD, L. P. | $2.67M | 0.65% | 2026-06-30 |
| 14 | NOMURA HOLDINGS INC | $2.13M | 0.52% | 2026-06-30 |
| 15 | Millennium Management LLC Custodian | $1.73M | 0.42% | 2026-06-30 |
| 16 | BNP Paribas Financial Markets Custodian | $1.07M | 0.26% | 2026-06-30 |
| 17 | TUDOR INVESTMENT CORP ET AL | $842.30K | 0.21% | 2026-06-30 |
| 18 | SUMMIT SECURITIES GROUP LLC | $570.70K | 0.14% | 2026-09-30 |
| 19 | Limestone Investment Advisors LP | $533.10K | 0.13% | 2026-06-30 |
| 20 | Simplex Trading, LLC Custodian | $388.08K | 0.09% | 2026-09-30 |
| 21 | Squarepoint Ops LLC | $309.20K | 0.08% | 2026-06-30 |
| 22 | Two Sigma Investments, LP Custodian | $266.55K | 0.06% | 2026-06-30 |
| 23 | Walleye Capital LLC | $245.23K | 0.06% | 2026-06-30 |
| 24 | PEAK6 LLC | $149.27K | 0.04% | 2026-06-30 |
| 25 | Point72 Asset Management, L.P. | $85.30K | 0.02% | 2026-06-30 |
INSM Insider Trading (Form 4)
Latest: 2026-10-20Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Paul Hudson | Director | Award (A) | +6,139 | — | EDGAR | |
| 2026-10-20 | Utpal Koppikar | Director | Award (A) | +6,139 | — | EDGAR | |
| 2026-09-11 | David R Brennan | Director | Sell (S) | −25,000 | $124.00 | -$3.10M | EDGAR |
| 2026-08-19 | Melvin Md Sharoky | Director | Sell (S) | −5,000 | $127.53 | -$637.6K | EDGAR |
| 2026-08-12 | Roger Adsett | Chief Operating Officer | Mixed Exer +239,850 · Sell −239,850 |
— | $76.86 | -$27.06M | EDGAR |
| 2026-08-07 | Martina M.D. Flammer | Chief Medical Officer | Mixed Exer +27,173 · Sell −27,173 |
— | $74.91 | -$2.92M | EDGAR |
| 2026-07-24 | William Lewis | Chair and CEO | Mixed Sell −10,700 · Exer +10,700 |
— | $65.50 | -$868.0K | EDGAR |
| 2026-07-10 | William Lewis | Chair and CEO | Mixed Sell −10,699 · Exer +10,699 |
— | $71.17 | -$989.2K | EDGAR |
| 2026-07-08 | Martina M.D. Flammer | Chief Medical Officer | Mixed Exer +12,302 · Sell −12,302 |
— | $67.89 | -$1.04M | EDGAR |
| 2026-06-26 | William Lewis | Chair and CEO | Mixed Sell −21,398 · Exer +21,398 |
— | $64.13 | -$1.68M | EDGAR |
| 2026-06-24 | Michael Alexander Smith | Chief Legal Officer | Sell (S) | −1,806 | $95.82 | -$173.1K | EDGAR |
| 2026-06-24 | Samuele Butera | SVP, GM, Global Respiratory | Award (A) | +7,342 | — | EDGAR | |
| 2026-06-10 | William Lewis | Chair and CEO | Sell (S) | −6,515 | $94.03 | -$612.6K | EDGAR |
| 2026-06-05 | Martina M.D. Flammer | Chief Medical Officer | Sell (S) | −4,424 | $102.90 | -$455.2K | EDGAR |
| 2026-06-05 | William Lewis | Chair and CEO | Sell (S) | −7,605 | $102.27 | -$777.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
INSM Insider Holdings
17 insiders · @ $115.00
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | William Lewis | Chair and CEO | 503,682 | $57.93M | -$120.22M | 94 | 2026-07-24 |
| 2 | Roger Adsett | Chief Operating Officer | 257,624 | $29.63M | -$62.66M | 45 | 2026-08-12 |
| 3 | Melvin Md Sharoky | Director | 251,504 | $28.92M | -$8.27M | 53 | 2026-08-19 |
| 4 | John Drayton Wise | Chief Commercial Officer | 140,935 | $16.21M | -$3.03M | 14 | 2025-02-07 |
| 5 | David R Brennan | Director | 99,238 | $11.41M | -$2.80M | 17 | 2026-09-11 |
| 6 | David W J McGirr | Director | 97,723 | $11.24M | -$451.5K | 16 | 2026-02-11 |
| 7 | Clarissa Desjardins | Director | 73,337 | $8.43M | $201.7K | 9 | 2026-05-15 |
| 8 | Sara Bonstein | Chief Financial Officer | 69,082 | $7.94M | -$44.19M | 33 | 2026-06-05 |
| 9 | Carol Schafer | Director | 66,622 | $7.66M | $0 | 8 | 2026-05-15 |
| 10 | Elizabeth M Anderson | Director | 62,034 | $7.13M | -$2.98M | 11 | 2026-05-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
INSM Board & Officers
As of SEC filings through Nov 3, 2026Directors 10
- Melvin Md Sharoky · on file since May 2006
- David W J McGirr · since Oct 30, 2013
- William Lewis · listed since Nov 2013
- David R Brennan · since May 29, 2014
- Leo Lee · since May 15, 2018
- Elizabeth M Anderson · since Nov 6, 2018
- Clarissa Desjardins · since Nov 12, 2019
- Carol Schafer · since Apr 1, 2020
- Paul Hudson · since Oct 19, 2026
- Utpal Koppikar · since Oct 19, 2026
Officers 8
- William Lewis · Chair and CEO · listed since Jan 2020
- Sara Bonstein · Chief Financial Officer · since Jan 31, 2020
- Roger Adsett · Chief Operating Officer · listed since Jan 2022
- Orlov S Nicole Schaeffer · Chief People Strategy Officer · listed since May 2018
- Martina M.D. Flammer · Chief Medical Officer · since Dec 16, 2019
- Michael Alexander Smith · Chief Legal Officer · listed since May 2024
- Samuele Butera · SVP, GM, Global Respiratory · since Jun 23, 2026
- Patrick Kevin Kane · Corporate Controller · since Oct 30, 2026
Changes in the last 10 years (28)
| Oct 30, 2026 | Patrick Kevin Kane became Corporate Controller |
| Oct 19, 2026 | Utpal Koppikar became a director |
| Oct 19, 2026 | Paul Hudson became a director |
| Jun 23, 2026 | Samuele Butera became SVP, GM, Global Respiratory |
| Apr 16, 2025 | The company announced the departure of John Drayton Wise as Chief Commercial Officer in an SEC filing |
| May 15, 2024 | Michael Alexander Smith listed as Chief Legal Officer (previously General Counsel, Senior VP) in SEC filings |
| May 23, 2022 | John Drayton Wise became Chief Commercial Officer |
| Jan 7, 2022 | Roger Adsett listed as Chief Operating Officer (previously Chief Commercial Officer) in SEC filings |
| Jul 8, 2021 | Michael Alexander Smith became General Counsel, Senior VP |
| Jan 6, 2021 | Roger Adsett listed as Chief Commercial Officer (previously Chief Operating Officer) in SEC filings |
| Apr 1, 2020 | Carol Schafer became a director |
| Jan 31, 2020 | Sara Bonstein became Chief Financial Officer |
| Jan 7, 2020 | William Lewis listed as Chair and CEO (previously Chairman, President & CEO) in SEC filings |
| Dec 16, 2019 | Martina M.D. Flammer became Chief Medical Officer |
| Nov 20, 2019 | Roger Adsett listed as Chief Operating Officer (previously Chief Commercial Officer) in SEC filings |
| Nov 20, 2019 | John Goll listed as Chief Accounting Officer (previously Chief Act. Off. & Controller) in SEC filings |
| Nov 12, 2019 | Clarissa Desjardins became a director |
| Jun 25, 2019 | William Lewis listed as Chairman, President & CEO (previously President & CEO) in SEC filings |
| Jun 3, 2019 | John Goll became Chief Act. Off. & Controller |
| Jan 7, 2019 | Christine A Pellizzari listed as Chief Legal Officer (previously General Counsel & Corp. Sec.) in SEC filings |
| Nov 6, 2018 | Elizabeth M Anderson became a director |
| May 31, 2018 | Orlov S Nicole Schaeffer listed as Chief People Strategy Officer (previously SVP, HR & Corp. Svcs.) in SEC filings |
| May 15, 2018 | Leo Lee became a director |
| May 15, 2018 | John Soriano became Chief Compliance Officer |
| Jun 5, 2017 | Paul Streck became Chief Medical Officer |
| Jun 1, 2017 | Paolo Tombesi became Chief Financial Officer |
| Jan 9, 2017 | Eugene Jeffrey Sullivan listed as Chief Med. & Scientific Ofc. (previously Chief Medical Officer) in SEC filings |
| Dec 16, 2016 | Christine A Pellizzari listed as General Counsel & Corp. Sec. (previously General Counsel & Secretary) in SEC filings |
Not reported recently (11)
- Alfred Altomari · Last reported as a director in an SEC filing dated May 15, 2024
- Steinar J Engelsen · Last reported as a director in an SEC filing dated Nov 3, 2021
- John Soriano · Last reported as Chief Compliance Officer in an SEC filing dated Sep 9, 2021
- Christine A Pellizzari · Last reported as Chief Legal Officer in an SEC filing dated May 18, 2021
- John Goll · Last reported as Chief Accounting Officer in an SEC filing dated Jan 7, 2020
- Donald J Hayden Jr · Last reported as a director in an SEC filing dated Apr 11, 2019
- Paolo Tombesi · Last reported as Chief Financial Officer in an SEC filing dated Jan 7, 2019
- Paul Streck · Last reported as Chief Medical Officer in an SEC filing dated Aug 9, 2018
- Myrtle S Potter · Last reported as a director in an SEC filing dated May 17, 2018
- Eugene Jeffrey Sullivan · Last reported as Chief Med. & Scientific Ofc. in an SEC filing dated May 19, 2017
- Andrew T Drechsler · Last reported as Chief Financial Officer in an SEC filing dated Mar 3, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
INSM Proposed Insider Sales (Form 144)
Latest: 2026-11-03
? Form 144 Guide
Last 30d:
1 filing
· $1.1M notice value
· Last 90d:
3 filings
· $4.9M notice value
· 3 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Brennan David R (1, $3.1M) · Sara Bonstein (1, $1.1M) · MELVIN SHAROKY (1, $638K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-03 | Sara Bonstein | Former Officer | 10,261 | $1.12M | 2026-11-03 | Merrill Lynch | — | EDGAR |
| 2026-09-10 | Brennan David R | Director | 25,000 | $3.10M | 2026-09-09 | Wells Fargo Clearing Services | — | EDGAR |
| 2026-08-17 | MELVIN SHAROKY | Director | 5,000 | $637.6K | 2026-08-17 | MERRILL LYNCH | — | EDGAR |
| 2026-08-10 | Roger Adsett | Officer | 239,850 | $31.96M | 2026-08-10 | Merrill Lynch | — | EDGAR |
| 2026-08-06 | Martina Flammer | Officer | 27,173 | $3.49M | 2026-08-06 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-07-23 | William Lewis | Officer | 10,700 | $1.13M | 2026-07-23 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-07-09 | William Lewis | Officer | 10,699 | $1.26M | 2026-07-09 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-07-06 | Martina Flammer | Officer | 12,302 | $1.35M | 2026-07-06 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-06-25 | William Lewis | Officer | 21,398 | $2.21M | 2026-06-25 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-06-22 | Michael Smith | Officer | 1,806 | $173.0K | 2026-06-22 | Merrill Lynch | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-10-29
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-10-29 | Earnings results | EDGAR |
| 2026-10-20 | Director or officer change · Regulation FD disclosure | EDGAR |
| 2026-10-05 | Director or officer change · Regulation FD disclosure | EDGAR |
| 2026-08-06 | Earnings results | EDGAR |
| 2026-07-16 | Regulation FD disclosure | EDGAR |
| 2026-05-15 | Shareholder vote results | EDGAR |
| 2026-05-07 | Earnings results | EDGAR |
| 2026-04-07 | Regulation FD disclosure · Other events | EDGAR |
| 2026-03-23 | Regulation FD disclosure · Other events | EDGAR |
| 2026-02-19 | Earnings results · Director or officer change | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-19 | 0001104506-26-000009 | EDGAR |
| 2025-02-20 | 0001104506-25-000009 | EDGAR |
| 2024-02-22 | 0001104506-24-000008 | EDGAR |
| 2023-02-23 | 0001104506-23-000009 | EDGAR |
| 2022-02-17 | 0001104506-22-000008 | EDGAR |
| 2021-02-25 | 0001104506-21-000005 | EDGAR |
| 2020-02-25 | 0001104506-20-000007 | EDGAR |
| 2019-02-22 | 0001104506-19-000009 | EDGAR |
| 2018-02-23 | 0001104506-18-000002 | EDGAR |
| 2017-02-23 | 0001047469-17-000856 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-10-29 | 0001104506-26-000047 | EDGAR |
| 2026-08-06 | 0001104506-26-000041 | EDGAR |
| 2026-05-07 | 0001104506-26-000032 | EDGAR |
| 2025-10-30 | 0001104506-25-000053 | EDGAR |
| 2025-08-07 | 0001104506-25-000043 | EDGAR |
| 2025-05-08 | 0001104506-25-000026 | EDGAR |
| 2024-10-31 | 0001104506-24-000033 | EDGAR |
| 2024-08-08 | 0001104506-24-000026 | EDGAR |
| 2024-05-09 | 0001104506-24-000016 | EDGAR |
| 2023-10-26 | 0001104506-23-000025 | EDGAR |
ETF Holders
176 ETFs hold INSM
25 shown · $3.19B total exposure · 0.20% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.03% | $793.3M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.30% | $280.8M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.16% | $280.5M | — | 2026-09-30 |
| 4 | VO Vanguard Morningstar Mid-Cap ETF | Vanguard | 0.12% | $266.9M | — | 2026-09-30 |
| 5 | VUG Vanguard Morningstar Growth ETF | Vanguard | 0.06% | $220.4M | — | 2026-09-30 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 1.70% | $185.9M | $11.1B | 2026-11-06 |
| 7 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.36% | $156.0M | — | 2026-09-30 |
| 8 | IWP iShares Russell Mid-Cap Growth ETF | iShares (BlackRock) | 0.79% | $138.3M | $17.3B | 2026-11-06 |
| 9 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.29% | $129.1M | $10.0B | 2026-11-05 |
| 10 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.18% | $105.0M | $56.9B | 2026-11-06 |
| 11 | VOT Vanguard Morningstar Mid-Cap Growth ETF | Vanguard | 0.29% | $97.8M | — | 2026-09-30 |
| 12 | IWF iShares Russell 1000 Growth ETF | iShares (BlackRock) | 0.08% | $92.8M | $114.6B | 2026-11-06 |
| 13 | VHT Vanguard Health Care ETF | Vanguard | 0.34% | $73.7M | — | 2026-09-30 |
| 14 | SCHG Schwab U.S. Large-Cap Growth ETF | Nport | 0.10% | $64.0M | — | 2026-08-31 |
| 15 | CGGR Capital Group Growth ETF | Capitalgroup | 0.26% | $64.0M | $24.7B | 2026-11-05 |
| 16 | JGRO JPMorgan Active Growth ETF | JPMorgan | 0.45% | $40.5M | $9.0B | 2026-11-06 |
| 17 | VONG Vanguard Russell 1000 Growth ETF | Vanguard | 0.07% | $40.0M | — | 2026-09-30 |
| 18 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.04% | $32.7M | $93.2B | 2026-11-06 |
| 19 | SCHX Schwab U.S. Large-Cap ETF | Nport | 0.04% | $28.3M | — | 2026-08-31 |
| 20 | VT Vanguard Total World Stock ETF | Vanguard | 0.02% | $21.3M | — | 2026-09-30 |
| 21 | DYNF iShares U.S. Equity Factor Rotation Active ETF | iShares (BlackRock) | 0.04% | $17.5M | $40.6B | 2026-11-06 |
| 22 | IYH iShares U.S. Healthcare ETF | iShares (BlackRock) | 0.36% | $16.9M | $4.7B | 2026-11-06 |
| 23 | IWB iShares Russell 1000 ETF | iShares (BlackRock) | 0.04% | $16.8M | $46.6B | 2026-11-06 |
| 24 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.04% | $15.9M | — | 2026-08-31 |
| 25 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.36% | $14.8M | $4.2B | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.81
TTM Revenue
$1.52B
TTM Net Income
$-605.61M
TTM Op. Cash Flow
$-595.62M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $524.43M | $-100.32M | $-0.46 | $-36.46M |
| Q2 '26 | 2026-06-30 | $425.49M | $-13.24M | $-0.06 | $-88.83M |
| Q1 '26 | 2026-03-31 | $305.96M | $-163.56M | $-0.76 | $-222.74M |
| Q4 '25 | 2025-12-31 | $263.84M | $-328.49M | $-1.53 | $-247.60M |
| Q3 '25 | 2025-09-30 | $142.34M | $-370.02M | $-1.75 | $-219.76M |
| Q2 '25 | 2025-06-30 | $107.42M | $-321.69M | $-1.70 | $-205.57M |
| Q1 '25 | 2025-03-31 | $92.82M | $-256.58M | $-1.42 | $-262.09M |
| Q4 '24 | 2024-12-31 | $104.44M | $-235.55M | $-1.30 | $-195.98M |
| Q3 '24 | 2024-09-30 | $93.42M | $-220.52M | $-1.27 | $-180.92M |
| Q2 '24 | 2024-06-30 | $90.34M | $-300.61M | $-1.94 | $-134.85M |
| Q1 '24 | 2024-03-31 | $75.50M | $-157.09M | $-1.06 | $-172.13M |
| Q4 '23 | 2023-12-31 | $83.69M | $-186.06M | $-1.28 | $-130.82M |
Q3 2026 • period ending 2026-09-30 • filed 2026-10-29
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
31.98
P/S
21.30
EV/EBITDA
—
EV/Sales
21.31
ROE
-115.6%
ROA
-41.6%
Div Yield
0.00%
FCF Yield
-3.22%
Debt/Equity
0.74
Current Ratio
—
Market Cap
$24.23B
as of 2026-11-09
INSM vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 45.9 | +45.5% | +31.0% | 27 |
| AMGN Amgen Inc | $249.0B | 26.9 | +8.2% | +41.6% | 33 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.4% | 49 |
| VRTX Vertex Pharmaceuticals Inc | $138.7B | 35.4 | +10.5% | +21.6% | 63 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +804.8% | 51 |
| TEVA Teva Pharmaceutical Industries Limited | $49.7B | 99.8 | +2.7% | +38.7% | 26 |
| NTRA Natera, Inc. Common Stock | $45.1B | — | +36.6% | +39.5% | 44 |
| INSM Insmed, Inc. | $25.1B | — | +240.0% | −35.1% | 35 |
| GH Guardant Health, Inc. Common Stock | $20.4B | — | +42.7% | +56.9% | 25 |
| Peer median | $120.1B | 40.6 | +9.3% | +39.4% | 38 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
13.48M
SI % of Float
6.29%
Days to Cover
4.13
Short Vol Ratio
58.2%
Free Float
214.32M
Float %
98.1%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-24